The nature and severity of the reported events in clinical trials reflect the safety profile of macitentan (10 mg and 75 mg) and macitentan/tadalafil FDC as documented in the IBs and the high morbidity and mortality of the underlying diseases of the studied populations.Overall, the benefit-risk profile for macitentan based on data from the completed and ongoing trials remains favorable in the PAH (including the pediatric population) and CTEPH indications.